Aldeyra Gets Nasdaq Bid-Price Notice, Has Until May 17, 2027 to Reclaim $1.00
ALDX sits 32% above its 52-week low of $0.527.
Summary
Aldeyra received a Nasdaq notice that its stock has traded below $1.00 for 30 consecutive business days. It has until May 17, 2027 to regain compliance, with a possible second 180-day grace period.
Key Events · Legal and Risk Events · ALDX
-
Nasdaq Minimum Bid Price Notice
On November 17, 2026, Nasdaq's Listing Qualifications Staff notified Aldeyra that its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days, breaching Listing Rule 5550(a)(2).
-
Listing Remains Fully Effective
The notice has no immediate effect on the listing of Aldeyra's common stock on the Nasdaq Capital Market.
-
180-Day Cure Window to May 17, 2027
Aldeyra has until May 17, 2027 to regain compliance; a closing bid price of at least $1.00 for a minimum of 10 consecutive business days would prompt written confirmation of compliance.
-
Second Grace Period Possible
If compliance is not regained in the initial window, the company may qualify for an additional 180 calendar days by meeting Nasdaq's market value of publicly held shares and other initial listing standards and giving written notice of its intent to cure.
Analysis · ALDX · Life Sciences
A Nasdaq deficiency letter has landed after Aldeyra's stock closed below $1.00 for 30 straight business days. Listing is not suspended: the company has until May 17, 2027 to hold at least $1.00 for 10 consecutive business days, and a possible second 180-day window exists if it meets the other continued listing standards and commits in writing to curing the problem. The practical risk is that a reverse split becomes the likely fix, mechanically resetting the share count without changing the underlying business. This arrives while the company is still appealing the FDA's reproxalap rejection and holds $41.0M in cash funding operations into 2029, so the pressure here is on the share price and listing status rather than on liquidity.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALDX was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.9M. The 52-week trading range was $0.53 to $5.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.